AVIR
Price
$2.73
Change
-$0.03 (-1.09%)
Updated
May 9, 04:59 PM (EDT)
Capitalization
236.2M
3 days until earnings call
KRYS
Price
$132.03
Change
-$5.14 (-3.75%)
Updated
May 9, 04:59 PM (EDT)
Capitalization
3.96B
93 days until earnings call
Ad is loading...

AVIR vs KRYS

Header iconAVIR vs KRYS Comparison
Open Charts AVIR vs KRYSBanner chart's image
Atea Pharmaceuticals
Price$2.73
Change-$0.03 (-1.09%)
Volume$6.9K
Capitalization236.2M
Krystal Biotech
Price$132.03
Change-$5.14 (-3.75%)
Volume$2.96K
Capitalization3.96B
AVIR vs KRYS Comparison Chart
Loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVIR vs. KRYS commentary
May 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVIR is a Hold and KRYS is a Hold.

Ad is loading...
COMPARISON
Comparison
May 10, 2025
Stock price -- (AVIR: $2.76 vs. KRYS: $137.17)
Brand notoriety: AVIR and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVIR: 110% vs. KRYS: 163%
Market capitalization -- AVIR: $236.2M vs. KRYS: $3.96B
AVIR [@Biotechnology] is valued at $236.2M. KRYS’s [@Biotechnology] market capitalization is $3.96B. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVIR’s FA Score shows that 0 FA rating(s) are green whileKRYS’s FA Score has 1 green FA rating(s).

  • AVIR’s FA Score: 0 green, 5 red.
  • KRYS’s FA Score: 1 green, 4 red.
According to our system of comparison, both AVIR and KRYS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVIR’s TA Score shows that 4 TA indicator(s) are bullish while KRYS’s TA Score has 4 bullish TA indicator(s).

  • AVIR’s TA Score: 4 bullish, 6 bearish.
  • KRYS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both AVIR and KRYS are a bad buy in the short-term.

Price Growth

AVIR (@Biotechnology) experienced а -7.69% price change this week, while KRYS (@Biotechnology) price change was -17.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.32%. For the same industry, the average monthly price growth was +9.54%, and the average quarterly price growth was -14.72%.

Reported Earning Dates

AVIR is expected to report earnings on Aug 06, 2025.

KRYS is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (-6.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($3.96B) has a higher market cap than AVIR($236M). KRYS YTD gains are higher at: -12.441 vs. AVIR (-17.612). KRYS has higher annual earnings (EBITDA): 110M vs. AVIR (-192.53M). KRYS has more cash in the bank: 598M vs. AVIR (455M). AVIR has less debt than KRYS: AVIR (1.64M) vs KRYS (7.26M). KRYS has higher revenues than AVIR: KRYS (291M) vs AVIR (0).
AVIRKRYSAVIR / KRYS
Capitalization236M3.96B6%
EBITDA-192.53M110M-175%
Gain YTD-17.612-12.441142%
P/E RatioN/A33.45-
Revenue0291M-
Total Cash455M598M76%
Total Debt1.64M7.26M23%
FUNDAMENTALS RATINGS
AVIR vs KRYS: Fundamental Ratings
AVIR
KRYS
OUTLOOK RATING
1..100
5557
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
9733
SMR RATING
1..100
9167
PRICE GROWTH RATING
1..100
8085
P/E GROWTH RATING
1..100
9696
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVIR's Valuation (45) in the Biotechnology industry is in the same range as KRYS (73) in the Pharmaceuticals Major industry. This means that AVIR’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (33) in the Pharmaceuticals Major industry is somewhat better than the same rating for AVIR (97) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than AVIR’s over the last 12 months.

KRYS's SMR Rating (67) in the Pharmaceuticals Major industry is in the same range as AVIR (91) in the Biotechnology industry. This means that KRYS’s stock grew similarly to AVIR’s over the last 12 months.

AVIR's Price Growth Rating (80) in the Biotechnology industry is in the same range as KRYS (85) in the Pharmaceuticals Major industry. This means that AVIR’s stock grew similarly to KRYS’s over the last 12 months.

AVIR's P/E Growth Rating (96) in the Biotechnology industry is in the same range as KRYS (96) in the Pharmaceuticals Major industry. This means that AVIR’s stock grew similarly to KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVIRKRYS
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 12 days ago
77%
Bullish Trend 11 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Ad is loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RZB24.980.13
+0.52%
Reinsurance Group of America
EPU45.020.23
+0.51%
iShares MSCI Peru ETF
UTWO48.31-0.10
-0.21%
US Treasury 2 Year Note ETF
DIVI34.01-0.15
-0.44%
Franklin Intl Core Div Tlt Idx ETF
SSFI21.17-0.12
-0.58%
Day Hagan Smart Sector Fixed Income ETF

AVIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVIR has been loosely correlated with HEPA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AVIR jumps, then HEPA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVIR
1D Price
Change %
AVIR100%
+1.85%
HEPA - AVIR
47%
Loosely correlated
+1.03%
AXON - AVIR
46%
Loosely correlated
+14.13%
IMNM - AVIR
46%
Loosely correlated
+3.77%
FHTX - AVIR
45%
Loosely correlated
+13.53%
KALV - AVIR
43%
Loosely correlated
-0.49%
More

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with ACLX. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+0.27%
ACLX - KRYS
60%
Loosely correlated
+6.27%
IDYA - KRYS
55%
Loosely correlated
+1.96%
CGON - KRYS
53%
Loosely correlated
+8.01%
XNCR - KRYS
51%
Loosely correlated
+10.08%
SNDX - KRYS
50%
Loosely correlated
+10.21%
More